Laboratory Billing Services
Laboratory claims are decided upstream of the claim file. The requisition, the ordering diagnosis and the order set determine what may be billed, and the billing work is the reconciliation between what was ordered, what was resulted and what goes out on the claim. We bill for independent clinical laboratories, hospital outreach programs, physician office laboratories, and pathology groups billing the technical component.
Three failures are common enough to plan around. An order carrying a diagnosis the Medicare contractor's coverage policy does not list denies as not medically necessary, and once the specimen has been drawn the window to obtain an advance beneficiary notice has closed, so the charge becomes a write-off instead of a patient balance. A panel reported when one component was not performed is an incorrect claim recouped on review, while components reported separately when the panel was performed forfeit the bundled rate and trip unbundling edits at the payer — and which of the two is correct is set by the order, not by the biller. A test dated to the day the laboratory ran it rather than the day the specimen was collected attaches to the wrong encounter, which changes whether the performing lab may bill it separately at all.
So we work the front end rather than the rejection. We take the billable facts out of the LIS and order-entry system — ordering provider and NPI, the test or panel as ordered, specimen type, collection date and time, the diagnosis the order carries, and the accession number that ties a resulted test back to a charge — and validate that diagnosis against the right contractor's policy before collection rather than nationally. We hold and query a deficient requisition back to the ordering practice instead of coding around it. We issue the notice before the test is furnished, on the current CMS form, so a denied test is still collectable from the patient. We reconcile requisition, result and claim as one list before anything is submitted, and we check certificate scope against the platform a new test will actually run on before it goes on the menu. On the payment side we reload the schedule each year rather than carrying last year's rates: CMS states there is no PAMA phase-in reduction in the 2026 Clinical Laboratory Fee Schedule, with reductions resuming on January 1, 2027 and capped at 15 percent a year through 2029 (verified September 17, 2026).
- Free audit
- No contract
- HIPAA-secure
- Cancel anytime
What Is Laboratory Billing?
Laboratory billing is the reconciliation between what was ordered, what was resulted and what goes out on the claim, and most of the outcome is set before the claim is built. A panel code pays one bundled amount and is reportable only when every listed component was performed, so the order set — not the biller — decides panel versus component coding. The ordering diagnosis has to satisfy the Medicare national or contractor local coverage policy for that test, and where it does not, the laboratory can bill the patient only if a signed advance beneficiary notice was obtained before the test was furnished (Medicare Claims Processing Manual, chapter 16, section 40.7). Date of service is the collection date under 42 CFR 414.510, with three narrow exceptions. And CMS states there is no PAMA phase-in reduction in the 2026 Clinical Laboratory Fee Schedule — reductions resume in 2027, capped at 15 percent a year through 2029. We run those checks at order entry for independent clinical laboratories, hospital outreach programs and physician office laboratories, and reconcile each payment against the contracted rate rather than against the Medicare amount.
- Panel codes pay one bundled amount only when every listed component was performed
- Ordering diagnosis has to satisfy the NCD or contractor LCD, or the test denies as not medically necessary
- Date of service is the collection date under 42 CFR 414.510, not the analysis date
- An ABN signed before the test is furnished is what makes a denied test patient-billable
Who This Page Is For
Common Billing Friction in Laboratory
Panel versus component billing, and the requisition that decides it
Each CPT laboratory panel — 80048 BMP, 80053 CMP, 80061 lipid, 80050 general health, 80055 obstetric — is reportable only when every component test listed in the panel was performed and resulted. Reporting the panel with a component missing is an incorrect claim that is recouped on review; reporting the components individually when the panel was performed forfeits the bundled rate and trips unbundling edits at the payer. Nothing in the billing office decides which is correct — the order does. The control is a three-way reconciliation: the tests on the requisition, the tests actually resulted in the LIS, and the lines on the claim have to be the same list. Where the requisition is deficient — no ordering diagnosis, an unsigned or stale standing order, a panel ticked but a component cancelled for quantity not sufficient — the charge is held and queried back to the ordering practice rather than coded around.
NCD/LCD medical necessity diagnosis-to-test pairing
Medicare publishes National Coverage Determinations and contractor Local Coverage Determinations for high-volume tests including TSH (84443), vitamin D (82306), HbA1c (83036) and PSA (84153) setting out which ICD-10 diagnoses support medical necessity. An order carrying a diagnosis outside that list denies as not medically necessary, and the laboratory cannot shift the charge to the patient unless an advance beneficiary notice was signed before the test was furnished — the Medicare Claims Processing Manual, chapter 16, section 40.7, requires the notice before the test is provided, not after the denial arrives. Because the covered-diagnosis list belongs to a specific contractor, the same test can be covered for a diagnosis in one jurisdiction and not in another, so the matrix has to be built per MAC rather than nationally. Validating the ordering diagnosis at order entry is the only control that works at volume, because once the specimen is drawn the window for an ABN has closed.
CLIA certificate scope, and why the CPT code does not tell you the complexity
42 CFR 493.5 sorts laboratory tests into three complexity categories — waived, moderate complexity (which includes the provider-performed microscopy subcategory) and high complexity — and requires every laboratory to be CLIA-exempt or to hold one of five certificates: registration, waiver, PPM procedures, compliance, or accreditation. The trap is that complexity is assigned to a specific test system, assay or examination rather than to a CPT code. Under 42 CFR 493.17 each individual test system is scored against seven criteria and categorized, and those categorizations are published in the Federal Register — so the same analyte can be waived on one manufacturer's platform and moderate or high complexity on another, and a certificate of waiver covers only the systems on the waived list. Medicare recognizes waived testing through a list CMS updates quarterly; as the Medicare Claims Processing Manual, chapter 16, section 70.8 puts it, some waived tests have their own HCPCS codes and others must carry the QW modifier. The question before adding a test is therefore which platform it will run on, not which code it will be billed under.
Date of service, the 14-day condition, and which claim the test belongs on
These are one rule, not two. 42 CFR 414.510 makes the date of service for a clinical laboratory test, or for the technical component of a physician pathology service, the date the specimen was collected — not the date the laboratory ran it, which matters as soon as a specimen ships to a reference lab and is analyzed days later. Collection spanning two calendar days takes the date collection ended. Three narrow exceptions move the date of service to the date the test was performed: a specimen stored 30 days or less where the physician ordered the test at least 14 days after the patient's discharge from the hospital and the other listed conditions are met; a chemotherapy sensitivity test on live tissue where the decision on which agents to test came at least 14 days after discharge; and a molecular pathology test, or a test CMS has designated an advanced diagnostic laboratory test, on a specimen collected during a hospital outpatient encounter and performed after that encounter ended without guiding care during it. A specimen stored more than 30 days is treated as archived and takes the date it came out of storage. The 14 days is a condition inside two of those exceptions, not a general rule that a hospital bills every specimen it collects. What the date of service actually settles is which encounter the test attaches to, and therefore whether it sits inside a facility's bundled payment or is separately billable by the performing lab.
PAMA fee schedule timing, ABN execution, and the molecular code families
The Protecting Access to Medicare Act rebased the Clinical Laboratory Fee Schedule on private-payer rates, but the phase-in has been deferred repeatedly. CMS states there is no phase-in reduction in 2026, and that from January 1, 2027 through 2029 payment may not be reduced by more than 15 percent a year against the preceding year's amount; the 2026 rates still rest on data collected in the first half of 2016 and reported in 2017, while the next cycle uses data collected January 1 to June 30, 2025 and reported by July 31, 2026. Commercial laboratory rates are contracted separately and are not derived from the Medicare amount, so a difference between the two is a contract, not an error. An ABN has to be obtained before the test is furnished, signed, and on the current CMS form, or a subsequent denial cannot be shifted to the patient. On the molecular side the code families are distinct and not interchangeable: Tier 1 codes name a specific gene or analyte, Tier 2 codes 81400–81408 group procedures by level of analysis, genomic sequencing procedures run from 81410, 81479 is the unlisted molecular pathology code, and PLA codes in the 0000U series belong to one manufacturer's proprietary test. Coverage criteria and prior-authorization rules differ across all four. All of these families sit inside the broader laboratory CPT range of 80000–89999, which spans chemistry, hematology, immunology, microbiology and molecular pathology.
Laboratory-Specific Payer Issues We Watch For
Medicare
Issue: National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) specify which diagnosis codes support medical necessity for each lab test — claims without qualifying diagnoses are automatically denied
Our approach: We maintain a diagnosis-to-test validation matrix based on current NCDs and LCDs and validate every claim against medical necessity requirements before submission
Commercial plans
Issue: Contracted laboratory rates sit in the plan's own fee schedule and are not derived from the Medicare amount, so a paid amount that differs from the Medicare fee schedule is a contract term rather than an underpayment
Our approach: We load the contracted laboratory fee schedule per plan and reconcile every payment against that contract rather than against Medicare, so a genuine underpayment can be told apart from a rate we simply had not loaded
BCBS
Issue: Blue Cross Blue Shield plans are separately operated, so laboratory benefit design, preferred-laboratory requirements and ordering-provider rules are set plan by plan — a policy confirmed for one Blue plan does not carry across to another
Our approach: We verify the specific member's plan policy before a send-out rather than applying one BCBS rule across the book, and we record which plan and which policy date the verification came from
Plans with separate molecular testing policies
Issue: Genetic and molecular tests are governed by a separate coverage policy, and often a separate notification or precertification pathway, from the routine chemistry they are ordered alongside — so an order that is payable for the panel can be unpayable for the molecular add-on
Our approach: We verify coverage and obtain authorization for the molecular test on its own policy before the specimen is run, and document the distinct clinical indication separately from the routine panel
What We Handle
Requisition-to-result-to-claim reconciliation on panel and component coding (80048, 80053, 80061, 80050)
The tests on the requisition, the tests resulted in the LIS and the lines on the claim reconciled as one list. Panel billing only where every component was performed, component billing where the order specified individual analytes, and a query back to the ordering practice where the requisition is deficient rather than a coding guess.
ABN execution workflow and patient-billable conversion on Medicare denials
The current CMS-approved ABN issued and signed before a potentially non-covered test is furnished, tracked by accession. Modifier GA on the claim where an ABN is on file, and conversion to patient responsibility once Medicare denies for medical necessity.
Molecular diagnostics billing — Tier 1, Tier 2 (81400–81408), genomic sequencing procedures and PLA 0000U
Tier 1 named-gene, Tier 2 level-based, genomic sequencing and proprietary PLA test billing with coverage verification and prior-authorization submission before the specimen is run. G0452 where the payer requires the molecular pathology physician interpretation reported separately from the technical work.
Venipuncture (36415), capillary collection (36416), and specimen handling (99000, 99001)
Routine venipuncture and capillary collection billing, and handling and transfer charge capture where the payer's policy recognizes it. Under the Medicare physician fee schedule 36416, 99000 and 99001 carry a bundled status indicator and are not separately payable, so these are billed where a contract allows them rather than posted as expected revenue everywhere.
Reference lab send-out coordination and date-of-service routing
Send-out attribution between the referring and the performing laboratory, date-of-service assignment under 42 CFR 414.510 including the stored-specimen, chemotherapy-sensitivity and molecular exceptions, and duplicate-claim prevention where the same accession could be billed by two entities.
NCD/LCD diagnosis-validation matrix at order entry
ICD-10 diagnosis to CPT lab test validation against current Medicare NCDs and contractor-specific LCDs (Novitas, NGS, Palmetto, WPS, FCSO). Order-time validation prevents medical-necessity denials before specimen collection.
Free Billing Audit · No obligation
Is your laboratory billing leaving money on the table?
We audit your last 90 days of laboratory claims for under-coding, modifier errors, and denials — and show you the recoverable dollars at no cost. Written findings in 3–5 business days.
Prefer to talk? Book a 15-minute callRequest received
A billing specialist will review your practice details and reach out within 1 business day. No confirmation email is sent — if you need to reach us sooner, call +1-872-297-2815.
Key Laboratory CPT Codes
| CPT Code | Description | Medicare Amount CY2026 national, non-facility |
|---|---|---|
| 80053 | Comprehensive metabolic panel — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $10.56 | — |
| 85025 | Complete blood count with automated differential — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $7.77 | — |
| 81001 | Urinalysis, automated, with microscopy — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $3.17 | — |
| 80061 | Lipid panel — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $13.39 | — |
| 84443 | Thyroid stimulating hormone (TSH) — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $16.80 | — |
| 82947 | Glucose, quantitative, blood — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $3.93 | — |
| 36415 | Collection of venous blood by venipuncture — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $9.34 | — |
| 87086 | Urine culture, quantitative colony count — paid under the CY2026 Clinical Laboratory Fee Schedule, not the physician fee schedule; CLFS national rate $8.07 | — |
| 88305 | Surgical pathology, level IV, gross and microscopic — per specimen, not per block | $70 |
Amounts are the Medicare national unadjusted non-facility amounts for CY2026, computed from the published CMS relative value file. They are not what a commercial payer pays, and your locality adjustment moves them. A dash means Medicare publishes no amount for that code — because it is non-covered, bundled, or priced outside the fee schedule.
Why General Billing Teams Miss Laboratory Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for laboratory coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in laboratory.
Under-coding high-complexity visits
Laboratory encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for laboratory procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn laboratory denials quickly.
“Laboratory billing is a volume business, so the controls that matter sit upstream of the claim: a requisition carrying a covered diagnosis, an order set that matches what the lab actually performs, and a reconciliation that ties every resulted test back to a charge.”
MedPrecision Billing Team
Laboratory Billing Compliance Director
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current laboratory billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Laboratory Billing Terms
- PAMA (Protecting Access to Medicare Act)
- Legislation that rebased the Medicare Clinical Laboratory Fee Schedule on private-payer rates reported by laboratories. The phase-in of the resulting reductions has been deferred repeatedly: CMS states there is no phase-in reduction in 2026, and that reductions resume January 1, 2027 through 2029 capped at 15 percent a year.
- Panel Optimization
- Aligning the order set, the tests actually performed and the code billed so that a panel is reported when every component was performed and components are reported when only those analytes were run. It is a reconciliation against what the laboratory did, not a choice between two prices.
- NCD/LCD (National/Local Coverage Determination)
- Medicare policies that specify which diagnoses and clinical scenarios support medical necessity for specific lab tests. Claims without a qualifying diagnosis code linked to the ordered test are denied as not medically necessary.
- ABN (Advance Beneficiary Notice)
- A form issued to Medicare patients before performing lab tests that may not be covered, notifying them of potential financial responsibility. Required to bill the patient if Medicare denies the claim for medical necessity.
- Specimen Handling Fee
- The charge for collecting, processing and transferring a specimen to an outside laboratory, reported with 99000 or 99001. Under the Medicare physician fee schedule both carry a bundled status indicator and are not separately payable; commercial policies differ, so whether the charge is collectible depends on the contract.
- CLIA Waived Tests
- Test systems categorized as waived under 42 CFR 493.17, which a laboratory holding a CLIA certificate of waiver may perform. Categorization attaches to the specific test system rather than to the CPT code, and Medicare recognizes waived testing through a list CMS updates quarterly — some waived tests have their own HCPCS codes, others must carry the QW modifier.
Last updated: 2026-09-17
Common Questions
Common questions about laboratory billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for laboratory billing services.
Request ReviewWhen should we bill a panel code versus individual test codes?
Bill the panel code when all component tests included in the panel are ordered and performed. If only some components are needed, bill individual test codes. We analyze your ordering patterns to identify opportunities for panel billing accuracy and create order set recommendations.
How do you handle billing for reference laboratory send-out tests?
For send-out tests, we ensure proper ordering provider information is captured, bill under your laboratory's NPI when appropriate, and coordinate with the reference lab to prevent duplicate billing. We manage the fee schedule differential to ensure profitability on send-out testing.
What is required for molecular diagnostic test billing?
Molecular testing requires specific PLA or CPT codes, prior authorization for many payers, ordering provider documentation of medical necessity, and often a specimen type verification. We verify coverage before testing, submit authorizations, and use payer-specific code crosswalks for molecular diagnostics.
Why do labs get CO-50 medical necessity denials?
CO-50 means the diagnosis on the order did not satisfy the payer's coverage policy for that test. Medicare publishes NCDs and contractor-specific LCDs for high-volume tests such as TSH (84443), vitamin D (82306) and HbA1c (83036) listing the ICD-10 codes that establish medical necessity — if the ordering diagnosis is not on the list for that contractor, the claim denies, and the laboratory cannot bill the patient unless a signed ABN was obtained before the test was furnished (Medicare Claims Processing Manual, chapter 16, section 40.7). Because the list is contractor-specific, the matrix has to be built per MAC. At volume the only control that works is validating diagnosis against policy at order entry, before the specimen is drawn.
What is an 'accredited collect & handling fee' in pathology billing?
The phrase 'accredited collect & handling fee' comes from Australian Medicare pathology billing, where accredited collection centres bill a separate specimen collection and handling item — it is not a U.S. billing code. The U.S. equivalents are CPT 36415 (routine venipuncture), 36416 (capillary collection) and the specimen handling codes 99000 and 99001 for processing and transfer to an outside laboratory. Under the Medicare physician fee schedule, 36416, 99000 and 99001 all carry a bundled status indicator, so Medicare never pays them separately; commercial policies vary, so check the contract before billing them.
Related Services
Related Specialties
Related Resources
Request a Specialty Billing Review
See if your lab panel unbundling, CLIA waiver billing, and reference lab coding are increasing collections.
- No contract
- No setup fees
- Reply within 1 business day